CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
CANADA
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

The Growing Demand for Contract Research Organizations

The Growing Demand for Contract...

The Potential for Artificial Intelligence in Clinical Trials

The Potential for Artificial...

Craig Lipset Joins Member and Executive Advisor of MedVector

Craig Lipset Joins Member and...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

The Growing Demand for Contract Research Organizations

The Growing Demand for Contract...

The Potential for Artificial Intelligence in Clinical Trials

The Potential for Artificial...

Craig Lipset Joins Member and Executive Advisor of MedVector

Craig Lipset Joins Member and...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Life Sciences Review | Wednesday, August 03, 2022
Tweet

The likelihood of success for compounds entering late-stage clinical development will increase with patient segmentation.


FREMONT, CA: Protypia, Inc., a company based in Nashville, Tennessee, is acquired by Inotiv, Inc. (the "Company," "We," or "Our," or "Inotiv"). Leading nonclinical and analytical drug discovery and development services, research models, and associated goods and services are the focus of Inotiv, Inc., a contract research business. This top contract research organization specializes in nonclinical and analytical drug discovery and development services, research models, and related products and services. Protypia is an up-and-coming protein/peptide bioanalytical firm providing high-quality, tissue-based peptide mass spectrometry and protein.


"This highly-specialized technology and know-how significantly enhances our ability to support clients in the development of safe and effective medicines, particularly in the areas of immuno-oncology and cell and gene therapy. 


The ability to precisely quantify protein levels in tissues, including paraffin-embedded tissues, opens exciting new avenues for scientists to explore as they investigate disease pathways." says John Sagartz, Chief Strategy Officer of Inotiv.


The estimated $11.0 million transactions were roughly $9.5 million in cash, approximately $0.9 million worth of Inotiv common shares, and $0.6 million in unsecured subordinated promissory notes. The business plans to keep all current Protypia personnel on board and continue business in Nashville, Tennessee. The Company's products and services are designed to speed up, improve data quality, and lower the price of bringing novel medicines to market while advancing the development of new medications and medical devices through the discovery and preclinical stages.


Inotiv is dedicated to assisting researchers in realizing the full potential of their important R&D projects while supporting their goals for discovery and development. All of this is done while collaborating to create a safer and healthier society.


Weekly Brief

loading
Top 10 CROs - 2021
> <
  • Therapeutics 2022

    Top Vendors

    Current Issue
  • Life Science Compliance 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • Therapeutics 2022

    Top Vendors

    Current Issue
  • Life Science Compliance 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue

Read Also

Best Practices to Boost Life Sciences Content Marketing

Major Trends of HEOR in the Healthcare Industry

Sustainable Laboratory Techniques for a Sustainable Future

Applications of Proteomics in Medicine

Contract Research Organizations: What You Need to Know

Marketing Opportunities in the Life Science to Monitor in 2022

Ginkgo Enters Into A Definitive Agreement To Acquire Zymergen

Nuvolo Declares Its Multi-Tenant Offering Of Connected Workplace For Life Sciences Companies

Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/protypia-inc-s-acquisition-by-inotiv-inc-broadens-the-company-s-proteinpeptide-bioanalytical-capabilities-nwid-934.html